EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Alaunos Therapeutics, Inc (TCRT) fair value: what the stock is really worth

As of Oct 5, 2026: fair value of Alaunos Therapeutics, Inc $0.39, price $0.80, upside -50.8%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US98973P3091

AT Alaunos Therapeutics, Inc logo Thin data Sep 27, 2026

Alaunos Therapeutics, Inc

TCRT · US

Weakest SetupStrongly overvalued and low quality.

Fair value $0.3910 · Strongly overvalued (−50.8%)
Quality 29/100
Weak Growth (revenue 3y −88.0 %/yr in USD)
Negative free cash flow
Trails peers (2/7)
Narrow moat 6/100
Thin data
⚠ Dilution
Watch Alaunos Therapeutics, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$553.50 $0.7953 Fair Value $0.3910 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.7953 – $553.50 · fair‑value band $0.2635 – $0.4930 · the $0.7953 price screens above the $0.3910 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Alaunos Therapeutics in your weekly email

Every Wednesday you see whether Alaunos Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.

Show more

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Stock analysis

Alaunos Therapeutics, Inc (TCRT) currently trades at $0.7953, while our model-based Fair Value estimate is $0.3910, 50.8% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.2635 (bear) to $0.4930 (bull), the price of $0.7953 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Alaunos Therapeutics, Inc reported revenue of $5.0K in FY2025 versus $398K in FY2021, a compound −66.5%/yr. Reported net income was −$4.2M in FY2025.

Key figures

Market cap $3.0M · EPS (TTM) $−1.75 · Return on equity −186% · Return on assets (EBIT) −174% · Operating margin −135,233% · Revenue (TTM) $3.0K · Revenue growth (YoY) −25.0% · Free cash flow −$3.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 82% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −51%, TCRT screens richer than that median.

Fair Value models

Bear $0.2635 Fair Value $0.3910 Bull $0.4930
Price $0.7953 · Upside -50.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.4200 $0.5700 $0.8500 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.4200 $0.5700 $0.8500 51

Open the full fair value analysis →

Notify me when TCRT reaches fair value

Put TCRT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 29 · Market factors (momentum, volatility) 17

Profitability 0
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 5
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−50.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−88.0%
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−19,484.7% (2021) → −84,500.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

TCRT screens overvalued: fair value 51% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Alaunos Therapeutics, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −50.8% · Below median
Profitability
Return on assets −81.1% · Bottom 25%
Growth and dividend
Revenue growth −25.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.42× · Cheaper than median
PEG 0.58× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10%
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Alaunos Therapeutics, Inc · Fair Value
$0.3910 −51%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Alaunos Therapeutics, Inc Fair Value". https://www.fairvalue-calculator.com/stock/TCRT

Frequently asked questions

Is Alaunos Therapeutics, Inc (TCRT) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.3910 versus a price of $0.7953, about −51% upside (overvalued).
What is the fair value of TCRT?
Our model-based fair value for Alaunos Therapeutics, Inc is $0.3910 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.7953.
What is the quality score of TCRT?
Alaunos Therapeutics, Inc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alaunos Therapeutics, Inc (TCRT)?
Our model-based price target is the fair value of $0.3910 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario $0.2635, optimistic scenario $0.4930. It is a calculation from audited fundamentals, not an analyst target.
What is the Alaunos Therapeutics, Inc stock forecast for 2026?
Our models put fair value at $0.3910, about −51% upside versus a price of $0.7953 (overvalued). Cautious scenario $0.2635, optimistic scenario $0.4930. The calculation is refreshed regularly with new filings.
What is the revenue of Alaunos Therapeutics, Inc (TCRT)?
Alaunos Therapeutics, Inc reported trailing-twelve-month revenue of about $3.0K (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Alaunos Therapeutics, Inc (TCRT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alaunos Therapeutics, Inc it is $0.3910 per share (as of Sep 27, 2026), against a price of $0.7953. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Alaunos Therapeutics, Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, TCRT trades above its calculated fair value: price $0.7953, fair value $0.3910, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TCRT?
No. The price is what the market pays today ($0.7953); the fair value is what the company's own numbers justify ($0.3910). For Alaunos Therapeutics, Inc the two are $0.4043 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alaunos Therapeutics, Inc worth?
The market values Alaunos Therapeutics, Inc at about $3.0M (market capitalisation, as of Sep 27, 2026). Per share that is $0.7953; our models calculate a fair value of $0.3910 per share.
What do the bullish and bearish scenarios say about TCRT?
Our models span a range for Alaunos Therapeutics, Inc: cautious scenario $0.2635, base $0.3910, optimistic $0.4930 per share (as of Sep 27, 2026, price $0.7953). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of TCRT?
The PEG ratio of Alaunos Therapeutics, Inc is 0.58 (P/E divided by earnings growth, as of Sep 27, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Alaunos Therapeutics, Inc (TCRT)?
Balance-sheet figures for Alaunos Therapeutics, Inc (as of Sep 27, 2026): return on equity −186.0%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is TCRT from its 52-week high?
Alaunos Therapeutics, Inc trades at $0.7953, about 82% below its 52-week high of $4.36 and at the low of $0.7953 (as of Oct 5, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3910 is for.
Which stocks are comparable to Alaunos Therapeutics, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alaunos Therapeutics, Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.7953, calculated fair value $0.3910 (−51%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TCRT calculated?
We run Alaunos Therapeutics, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3910, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Alaunos Therapeutics, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alaunos Therapeutics, Inc (TCRT)?
The closing price on Oct 5, 2026 was $0.7953. Our model-based fair value is $0.3910, about −51% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alaunos Therapeutics, Inc right now?
The price sits above even our optimistic bull case ($0.4930). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2635 to $0.4930) leaves room in how you read the outcome.

Key figures of Alaunos Therapeutics, Inc

How large is the market capitalisation of Alaunos Therapeutics, Inc (TCRT)?
The market capitalisation of Alaunos Therapeutics, Inc is $3.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Alaunos Therapeutics, Inc (TCRT)?
Earnings per share at Alaunos Therapeutics, Inc are $−1.75. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Alaunos Therapeutics, Inc (TCRT)?
The return on equity (ROE) of Alaunos Therapeutics, Inc is −186% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alaunos Therapeutics, Inc (TCRT)?
On an EBIT basis the return on assets of Alaunos Therapeutics, Inc is −174% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alaunos Therapeutics, Inc (TCRT)?
The operating margin of Alaunos Therapeutics, Inc is −135,233% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alaunos Therapeutics, Inc (TCRT)?
Revenue at Alaunos Therapeutics, Inc is growing −25.0% versus a year earlier (3y avg −88.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Alaunos Therapeutics, Inc (TCRT) generate?
The free cash flow of Alaunos Therapeutics, Inc is −$3.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Alaunos Therapeutics, Inc (TCRT) hold?
Alaunos Therapeutics, Inc holds more cash than debt, $1.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Alaunos Therapeutics, Inc in the live analysis

One click puts Alaunos Therapeutics, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.